NZ514916A - Exendins and exendin agonists linked to polyethylene glycol polymers - Google Patents

Exendins and exendin agonists linked to polyethylene glycol polymers

Info

Publication number
NZ514916A
NZ514916A NZ514916A NZ51491600A NZ514916A NZ 514916 A NZ514916 A NZ 514916A NZ 514916 A NZ514916 A NZ 514916A NZ 51491600 A NZ51491600 A NZ 51491600A NZ 514916 A NZ514916 A NZ 514916A
Authority
NZ
New Zealand
Prior art keywords
exendin
polyethylene glycol
exendins
glycol polymers
exendin agonists
Prior art date
Application number
NZ514916A
Inventor
Andrew Young
Kathryn Prickett
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US13201899P priority Critical
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Priority to PCT/US2000/011814 priority patent/WO2000066629A1/en
Publication of NZ514916A publication Critical patent/NZ514916A/en
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22452067&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ514916(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

A polymer-modified exendin or agonist analog of an exendin comprising an exendin or agonist analog of an exendin linked to one or more polymers selected from the group consisting of: polyethylene glycol polymers, polyamino acids, albumin, gelatin, succinyl-gelatin, (hydroxypropyl)-methacrylamide, fatty acids, polysaccharides, lipid amino acids, and dextran.
NZ514916A 1999-04-30 2000-04-28 Exendins and exendin agonists linked to polyethylene glycol polymers NZ514916A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13201899P true 1999-04-30 1999-04-30
PCT/US2000/011814 WO2000066629A1 (en) 1999-04-30 2000-04-28 Modified exendins and exendin agonists

Publications (1)

Publication Number Publication Date
NZ514916A true NZ514916A (en) 2004-06-25

Family

ID=22452067

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ514916A NZ514916A (en) 1999-04-30 2000-04-28 Exendins and exendin agonists linked to polyethylene glycol polymers

Country Status (8)

Country Link
EP (2) EP1175443A1 (en)
JP (1) JP2002544127A (en)
CN (1) CN1372570A (en)
AU (2) AU775063C (en)
BR (1) BR0010705A (en)
CA (1) CA2372214A1 (en)
NZ (1) NZ514916A (en)
WO (1) WO2000066629A1 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) * 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
ES2227115T5 (en) * 2000-01-10 2014-10-30 Amylin Pharmaceuticals, Inc. Use of exendins and their agonists for the treatment of hypertriglyceridemia
AT309818T (en) * 2000-03-08 2005-12-15 Novo Nordisk As Reduction of serum cholesterols
AU2412402A (en) 2000-12-01 2002-06-11 Takeda Chemical Industries Ltd Method for producing preparation containing bioactive substance
EP1432430A4 (en) 2001-08-28 2006-05-10 Lilly Co Eli Pre-mixes of glp-1 and basal insulin
HU0700151A2 (en) * 2001-10-18 2007-05-29 Squibb Bristol Myers Co Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
JP2005508360A (en) 2001-10-19 2005-03-31 イーライ・リリー・アンド・カンパニーEli Lilly And Company Glp-1 and the two-phase mixture of insulin
JP2005518408A (en) 2001-12-29 2005-06-23 ノボ ノルディスク アクティーゼルスカブNovo Nordisk Aktie Selsxab For the treatment of dyslipidemia, combined use of glp-1 compound and the other drug
KR20050083713A (en) * 2002-10-02 2005-08-26 질랜드 파마 에이/에스 Stabilized exendin-4 compounds
AU2003283216A1 (en) * 2002-12-03 2004-06-23 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
EP1688148A1 (en) * 2002-12-03 2006-08-09 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
PT1605897E (en) * 2003-03-19 2012-09-10 Lilly Co Eli Polyethelene glycol link glp-1 compounds
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
US20070275877A1 (en) * 2003-08-29 2007-11-29 Amylin Pharmaceuticals, Inc. Methods for Treating or Ameliorating Ghrelin-Associated Diseases and Disorders
AT461217T (en) 2003-12-18 2010-04-15 Novo Nordisk As Glp-1 compounds
DE102004043153B4 (en) 2004-09-03 2013-11-21 Philipps-Universität Marburg Invention relating to GLP-1 and exendin
JP2008515856A (en) 2004-10-07 2008-05-15 ノボ ノルディスク アクティーゼルスカブNovo Nordisk Aktie Selsxab Delayed GLP-1 compound
JP5107713B2 (en) * 2004-10-07 2012-12-26 ノヴォ ノルディスク アー/エス Delayed exendin-4 compound
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
AU2005305036B2 (en) * 2004-11-01 2011-03-10 Amylin Pharmaceuticals, Llc Treatment of obesity and related disorders
WO2007055743A2 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
CN101094689B (en) * 2004-11-01 2013-06-12 安米林药品有限责任公司 Treatment of obesity and related disorders
CN100540565C (en) * 2005-01-14 2009-09-16 无锡宏创医药科技有限公司 Modified its application Exendins
US8716221B2 (en) * 2005-01-14 2014-05-06 Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. Modified exendins and uses thereof
CA2607566A1 (en) * 2005-05-06 2006-11-16 Bayer Pharmaceuticals Corporation Glucagon-like peptide 1 (glp-1) receptor agonists and their pharmacological methods of use
US20090042790A1 (en) * 2005-06-13 2009-02-12 Nastech Pharmaceutical Company Inc. Transmucosal delivery of peptide derivatives
DK1971362T3 (en) * 2005-08-19 2015-01-26 Amylin Pharmaceuticals Llc Exendin for treating diabetes and reducing body weight
US7582608B2 (en) 2005-10-26 2009-09-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
ES2390286T3 (en) 2005-12-16 2012-11-08 Nektar Therapeutics GLP-1 polymer conjugates
WO2007139941A2 (en) * 2006-05-26 2007-12-06 Amylin Pharmaceuticals, Inc. Composition and methods for treatment of congestive heart failure
CN101125207B (en) 2006-11-14 2012-09-05 上海华谊生物技术有限公司 Exendin or its analogs with polyethylene group and its preparation and application
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
US8420598B2 (en) 2007-04-20 2013-04-16 B & L Delipharm Corp. Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
US9353170B2 (en) 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
CA2740685C (en) 2008-10-17 2018-09-11 Sanofi-Aventis Deutschland Gmbh Combination of an insulin and a glp-1 agonist
CN101766811B (en) 2008-12-29 2012-07-04 上海复星医药(集团)股份有限公司 Application of exenatide acetate or analogue thereof in preparing drug for treating or preventing diabetes complicated with cerebral infarction
BRPI1013626A2 (en) 2009-03-20 2016-04-19 Hanmi Holdings Co Ltd method for preparing site-specific physiologically active polypeptide conjugate
CN101870728A (en) * 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 Novel Exendin variant and conjugate thereof
CN102711804B (en) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 Comprising glp-1 agonist and a pharmaceutical composition methionine
ES2534191T3 (en) 2009-11-13 2015-04-20 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine
TWI523659B (en) 2010-04-27 2016-03-01 Zealand Pharma As Peptide conjugates
DK2611458T3 (en) 2010-08-30 2017-01-02 Sanofi Aventis Deutschland Use of ave0010 for the preparation of a medicine for treatment of diabetes mellitus type 2
CN102397558B (en) * 2010-09-09 2013-08-14 中国人民解放军军事医学科学院毒物药物研究所 Positioning pegylation modified compound of Exendin-4 analog and application thereof
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
CN104271588B (en) * 2011-07-08 2017-10-10 安米林药品有限责任公司 The engineered polypeptide of immunogenicity with enhanced acting duration and reduction
PT2750699E (en) 2011-08-29 2015-11-03 Sanofi Aventis Deutschland Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
WO2013064669A1 (en) 2011-11-03 2013-05-10 Zealand Pharma A/S Glp-1 receptor agonist peptide gastrin conjugates
TWI608013B (en) 2012-09-17 2017-12-11 西蘭製藥公司 Glucagon analogues
DK2934567T3 (en) 2012-12-21 2018-08-13 Sanofi Sa Exendin-4 derivatives as double glp1 / gip or trigonal glp1 / gip / glucagon agonists
TWI641381B (en) 2013-02-04 2018-11-21 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
KR20180115814A (en) 2013-05-02 2018-10-23 노보 노르디스크 에이/에스 Oral dosing of glp-1 compounds
EA201690660A1 (en) 2013-11-06 2017-03-31 Зилэнд Фарма А/С Connections and methods based on double agonist of gip and glp-1
JP2017503474A (en) 2013-11-06 2017-02-02 ジーランド ファーマ アクティーゼルスカブ Glucagon-GLP-1-GIP triple agonist compound
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (en) 2013-12-13 2016-03-16 Sanofi Sa Dual glp-1 / glucagon receptor agonists
WO2015104314A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
WO2015104311A1 (en) 2014-01-09 2015-07-16 Sanofi Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
AU2015205620A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin aspart
KR101768446B1 (en) * 2014-03-21 2017-08-17 애니젠 주식회사 Novel Exenatide Analogs and Uses thereof
TW201625670A (en) 2014-04-07 2016-07-16 Sanofi Sa Dual derived from glp-1 exendin-4's / glucagon receptor agonists
TW201625669A (en) 2014-04-07 2016-07-16 Sanofi Sa Derived from exendin -4 (Exendin-4) the dual peptide GLP-1 / glucagon receptor agonists
TW201625668A (en) 2014-04-07 2016-07-16 Sanofi Sa As the dual peptide of glp-1 / glucagon receptor agonist of exendin-4 derivative
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN107001439A (en) 2014-10-29 2017-08-01 西兰制药公司 GIP agonist compounds and methods
MX2017007699A (en) 2014-12-12 2017-09-18 Sanofi Aventis Deutschland Insulin glargine/lixisenatide fixed ratio formulation.
TW201705974A (en) 2015-03-13 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
JP2018513152A (en) 2015-04-16 2018-05-24 ジーランド ファーマ アクティーゼルスカブ Acylated glucagon analogues
AR105284A1 (en) 2015-07-10 2017-09-20 Sanofi Sa Exendin-4 derivatives as dual specific peptide agonists receptor glp-1 / glucagon

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3490597A (en) 1966-07-22 1970-01-20 Purolator Products Inc Cover plate for spin-on-filter
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5264372A (en) 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
US5445781A (en) 1991-08-28 1995-08-29 Centro Sviluppo Settori Impiego S.R.L. Process for the injection molding of non-precatalyzed polymerizable resins at high-pressure and flow
HU225496B1 (en) 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
AT316100T (en) 1996-06-05 2006-02-15 Roche Diagnostics Gmbh Exendin analogues, process for their preparation and containing the same drug
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
AT493998T (en) * 1996-08-08 2011-01-15 Amylin Pharmaceuticals Inc Pharmaceutical composition with an exendin-4-peptide
JP3149958B2 (en) * 1996-08-30 2001-03-26 ノボ ノルディスク アクティーゼルスカブ Glp-1 derivatives
WO1998030231A1 (en) 1997-01-07 1998-07-16 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the reduction of food intake
WO1999043708A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
US6602997B2 (en) 2000-04-27 2003-08-05 Shin-Etsu Bio, Inc. Whole cell and cell-debris polysaccharide
US9410225B2 (en) 2014-05-13 2016-08-09 Teck Resources Limited Process for recovery of copper from arsenic-bearing and/or antimony-bearing copper sulphide concentrates
US9816387B2 (en) 2014-09-09 2017-11-14 United Technologies Corporation Attachment faces for clamped turbine stator of a gas turbine engine

Also Published As

Publication number Publication date
WO2000066629A1 (en) 2000-11-09
EP1175443A1 (en) 2002-01-30
AU775063B2 (en) 2004-07-15
AU2004220727B2 (en) 2007-10-11
AU4688300A (en) 2000-11-17
EP2264064A1 (en) 2010-12-22
BR0010705A (en) 2002-02-05
CN1372570A (en) 2002-10-02
JP2002544127A (en) 2002-12-24
CA2372214A1 (en) 2000-11-09
AU775063C (en) 2005-05-12
AU2004220727A1 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
DE69841986D1 (en) Increased expression vectors, processes for their preparation and their uses
DE69840552D1 (en) Compounds and pharmaceutical compositions with appetite suppressing activity
DE69837170D1 (en) Solid-phase native chemical ligation of unprotected or n-cysteine-protected peptides in aqueous solutions
TW593338B (en) Analogues of GLP-1
DK1194580T3 (en) In vitro reconstruction of segmented negative-stranded RNA viruses
DE60039629D1 (en) Use of pharmaceutical preparations containing oxcarbazepine in so far condition
DK1200390T3 (en) Preparation of N-substituted 2,7-dialkyl-4-hydroxy-5-amino-8-aryl-octanoylamides
DE69839279D1 (en) New physiological active substance sulphostine, manufacture and use thereof
DE69930872T8 (en) Antibodies against shortened vegf-d and its uses
DE60035404D1 (en) Expanded PTFE vascular graft for drug delivery
DE69739856D1 (en) Agonists for the receptor of the hepatocyte growth factor and its applications
DK0957914T4 (en) Formulation of 5-HT agonists
TW577759B (en) Sustained release compositions in the form of microcapsules or implants and the process for their preparation
DE69838986D1 (en) Polypeptides, their preparation and use
DE60035584D1 (en) Use of exendins and their agonists for the treatment of pregnancy diabetes
DE60331049D1 (en) Conjugates of cytotoxic agents and biologically active peptides
TWI251487B (en) Modified release pharmaceutical compositions
DE69837453D1 (en) An in vitro sorting procedure
DE60138031D1 (en) Video and mailbox instant messaging method and agents
PT100900A (en) Process for the preparation of conjugated peptides, and peptides so obtained
BR0010750A (en) Peptides long-term insulinotropic
DK1007115T3 (en) medication delivery
YU75701A (en) Pharmaceutical composition
MX9707088A (en) Compounds and compositions for delivering active agents.
EP0417572A3 (en) Extended drug delivery of small, water-soluble molecules

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 7 YEARS UNTIL 28 APR 2020 BY CPA GLOBAL

Effective date: 20130315